CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
CCR8：一个对抗肿瘤浸润性调节性 T 细胞的有前景的治疗靶点
英文原题：CCR8: a promising therapeutic target against tumor-infiltrating regulatory T cells.
查看英文原题
CCR8: a promising therapeutic target against tumor-infiltrating regulatory T cells.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
肿瘤浸润性调节性T（TI-Treg）细胞是肿瘤微环境（TME）中抑制抗肿瘤免疫并促进肿瘤进展的关键组成部分。尽管已开发出多种疗法来消除TI-Treg细胞，但大多数疗法仅表现出有限的疗效，并存在诱发免疫相关不良事件（irAEs）的风险。近期研究表明，CC趋化因子受体（CCR）8在小鼠和人类的效应TI-Treg细胞上高表达且具有特异性，凸显CCR8作为选择性清除TI-Treg细胞以治疗多种癌症的有前景靶点。本文聚焦于CCR8在表达、功能和调控方面的最新认识，并总结CCR8靶向疗法的当前格局。后者凭借良好的疗效和安全性，代表了一类重要的下一代潜在癌症免疫疗法。
展开英文摘要原文
Tumor-infiltrating regulatory T (TI-Treg) cells constitute key components within the tumor microenvironment (TME) to suppress antitumor immunity and facilitate tumor progression. Although multiple therapies have been developed to eliminate TI-Treg cells, most of them exhibit only modest efficacy and harbor risks of inducing immune-related adverse events (irAEs).
Recent studies demonstrate that CC chemokine receptor (CCR)8 is highly and specifically expressed on effector TI-Treg cells in mice and humans, highlighting CCR8 as a promising target for selective TI-Treg cell depletion in the treatment of various cancers.
Here, we concentrate on the latest understanding of CCR8 regarding its expression, functions, and regulation, and summarize the current landscape of CCR8-targeted therapies. With favorable efficacy and safety, the latter represent an important class of next-generation putative cancer immunotherapies.
论文信息
- 作者
- Wen Y、Xia Y、Yang X、Li H、Gao Q
- 第一作者单位
- Department of Obstetrics and Gynecology, National Clinical Research Center for Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; Key Laboratory of Cancer Invasion and Metastasis (Ministry of Education), Hubei Key Laboratory of Tumor Invasion and Metastasis, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.China
- 通讯作者单位
- Department of Obstetrics and Gynecology, National Clinical Research Center for Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; Key Laboratory of Cancer Invasion and Metastasis (Ministry of Education), Hubei Key Laboratory of Tumor Invasion and Metastasis, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Electronic address: qingleigao@hotmail.com.China
- 文献类型
- 综述 · 非美国政府资助研究
- 期刊
- Trends in immunology2025 Feb
- 原文标识
- PubMed 39890548 · DOI 10.1016/j.it.2025.01.001